Pfizer Inc. (NYSE:PFE) Shares Acquired by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 20.4% in the 1st quarter, Holdings Channel.com reports. The fund owned 398,416 shares of the biopharmaceutical company’s stock after buying an additional 67,512 shares during the quarter. Pfizer comprises approximately 1.8% of Gilman Hill Asset Management LLC’s investment portfolio, making the stock its 10th biggest position. Gilman Hill Asset Management LLC’s holdings in Pfizer were worth $10,096,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Starboard Value LP acquired a new position in Pfizer in the 4th quarter valued at $407,730,000. Raymond James Financial Inc. acquired a new position in Pfizer in the 4th quarter valued at $274,694,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Trading Up 0.3%

Shares of PFE stock opened at $23.42 on Thursday. The firm has a market capitalization of $133.15 billion, a P/E ratio of 16.61, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock’s fifty day simple moving average is $23.02 and its 200 day simple moving average is $25.02.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.82 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.